Mergers & Acquisitions ·
On August 5, 2026, BiomX Inc. entered into a Share Purchase and Option Agreement to acquire 10% of M.E.A. Testing…
PHGETessera Defense & Homeland Security Inc.
On August 5, 2026, BiomX Inc. entered into a Share Purchase and Option Agreement to acquire 10% of M.E.A. Testing Systems Ltd. (MEA) for $50,000 cash and the issuance of 1,300,000 restricted common shares. The transaction includes an exclusive license to MEA's technology and an option to purchase Motomova Inc.'s remaining ~78.9% stake in MEA by June 30, 2028, with exercise price based on 2x net revenue or 4x EBITDA for fiscal year 2027. Closing is contingent upon NYSE American listing approval and execution of the license agreement. BiomX Inc. operates in the biotechnology industry, focusing on phage therapy solutions.